Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metronidazole + vancomycin
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination antibiotic therapy used primarily for treating Clostridioides difficile infection (CDI), particularly in severe or fulminant cases. The combination typically consists of oral vancomycin and intravenous metronidazole. While vancomycin acts by inhibiting bacterial cell wall synthesis, metronidazole disrupts DNA in anaerobic bacteria. This combination is often recommended for critically ill patients with CDI, though evidence regarding its superiority over monotherapy is mixed.
- Other names
- Antibiotics for Clostridioides infectionvancomycinmetronidazole
02
Targets
NeuraminidaseD-Ala-D-Ala (D-Ala-D-Ala terminus)
Beyond the preview
Go deeper on metronidazole + vancomycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metronidazole + vancomycin.